Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04844983
Recruitment Status : Recruiting
First Posted : April 14, 2021
Last Update Posted : May 27, 2021
Sponsor:
Information provided by (Responsible Party):
Sirnaomics

Brief Summary:
The purpose of this trial is to evaluate safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with cutaneous squamous cell carcinoma (in situ) skin cancer (isSCC).

Condition or disease Intervention/treatment Phase
Squamous Cell Carcinoma in Situ Drug: STP705 Other: Placebo Saline Phase 2

Detailed Description:

This is a two-part, double-blind, randomized, placebo-controlled study designed to evaluate safety and efficacy of various doses of STP705 administered as an intralesional injection in subjects with isSCC.

A total of up to 100 eligible subjects will be enrolled. Enrolled subjects will be randomly allocated to receive STP705 or placebo injection once weekly for 6 weeks.

After 6 weeks, the lesion will be excised.

In part 1 (dose ranging study): 40 subjects will be randomized to receive 1 of the 3 STP705 doses or placebo.

An interim analysis will be done after all subjects have completed end of treatment (EOT) visits to determine 2 selected dose levels of STP705 to be used in part of the study.

In part 2: 60 additional subjects will be randomized to receive 1 of the 2 selected doses (from part 1) or placebo.

In both parts at the End of Treatment (EOT), the lesion will be excised.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Part 1: 40 subjects randomized in a 1:1:1:1 ratio to receive 6 weeks of treatment of placebo, 30 ug, 60 ug, or 90 ug of STP705. Enrollment will be temporarily stopped after the 40th subject. Interim Analysis will be done for dose response assessment and selection of the 2 doses for Part 2 of the study.

Part 2: 60 additional subjects will be randomized in a 1:1:1 ratio to receive placebo or one of the 2 selected STP705 doses.

Masking: Double (Participant, Investigator)
Masking Description: This is a double-blind study. All subjects, investigators, and site staff (except unblinded pharmacist or designated site staff) in the study will be blinded to the treatment assignment.
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Patients With Cutaneous Squamous Cell Carcinoma in Situ (isSCC)
Actual Study Start Date : May 18, 2021
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2021

Arm Intervention/treatment
Experimental: Part 1: Arm A
STP705 30 μg dose, intralesional injection, given once a week for 6 weeks.
Drug: STP705
The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.

Experimental: Part 1: Arm B
STP705 60 μg dose, intralesional injection, given once a week for 6 weeks.
Drug: STP705
The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.

Experimental: Part 1: Arm C
STP705 90 μg dose, intralesional injection, given once a week for 6 weeks.
Drug: STP705
The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.

Part 1: Arm D
Placebo (normal saline), intralesional injection, given once a week for 6 weeks.
Other: Placebo Saline
Normal Saline

Experimental: Part 2: Arm A, B or C
STP705 selected dose 1, intralesional injection, given once a week for 6 weeks.
Drug: STP705
The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.

Experimental: Part 2: Arm A or B or C
STP705 selected dose 2, intralesional injection, given once a week for 6 weeks.
Drug: STP705
The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.

Part 2: Arm D
Placebo (normal saline), intralesional injection, given once a week for 6 weeks.
Other: Placebo Saline
Normal Saline




Primary Outcome Measures :
  1. Proportion of participants with histological clearance of treated isSCC lesion [ Time Frame: 6 weeks ]
    Proportion of participants with histological clearance of treated isSCC lesion at the End of Treatment (EOT).


Secondary Outcome Measures :
  1. Change in size of the treated isSCC lesion [ Time Frame: 6 weeks ]
    Change in size of the treated isSCC lesion over the 6-week treatment period.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female adult ≥ 18 years of age.
  2. Primary, histologically confirmed trunk or extremity (non- anogenital/-facial/-scalp) isSCC lesion suitable for excision with a minimum diameter of 0.5 cm and with a maximum diameter of 2.0 cm.
  3. Histological diagnosis made no more than 6 months prior to the screening visit.
  4. No other dermatological disease in the isSCC target site or surrounding area, which in the opinion of the investigator, could interfere with the study.
  5. Willing to refrain from using non-approved lotions or creams on the target site and surrounding area during the treatment period.
  6. Willing to refrain from exposure to excessive direct sunlight or ultraviolet light and to avoid the use of tanning parlors for the duration of the study.
  7. Laboratory values for the tests (listed in the Study Schedule) within the reference ranges as defined by the central laboratory, or "out of range" test results that are clinically acceptable to the investigator.
  8. Ability to follow study instructions and likely to complete all study requirements.
  9. Written informed consent obtained, including consent for tissue to be examined and stored by the Central Histology Lab.
  10. Written consent to allow photographs of the target isSCC lesion to be used as part of the study data and documentation.
  11. For females of childbearing potential, a negative pregnancy test at screening and using an acceptable form of birth control (oral / implant/ injectable/ transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy).

Exclusion Criteria:

  1. Pregnant, lactating, or planning to become pregnant.
  2. Presence of known or suspected systemic cancer.
  3. Histological evidence of severe squamous metaplasia, infiltrative, desmoplastic or micronodular growth patterns in the biopsy specimen.
  4. History of recurrence of the target isSCC lesion.
  5. Concurrent disease or treatment that suppresses the immune system.
  6. Patients with baseline QTC > 480 msec using Frederica's formula.
  7. Chronic medical condition that in the judgment of the investigator(s) would interfere with the performance of the study or would place the patient at undue risk.
  8. Known sensitivity to any of the ingredients in the study medication including an allergy to trehalose.
  9. Use of a tanning bed or other excessive or prolonged exposure to ultraviolet light or direct sunlight during the study.
  10. Treatment with systemic chemotherapeutic agents within the 6 months prior to the screening visit.
  11. Use of systemic retinoids within the 6 months prior to the screening period.
  12. Treatment with systemic immunomodulators or immunosuppressants within the 6 months prior to the screening period.
  13. Use of topical immunomodulators within 2 cm of the target isSCC lesion within the 4 weeks prior to the screening period.
  14. Treatment with the following topical agents within 2 cm of the target isSCC lesion within the 4 weeks prior to the screening visit: aminolevulinic acid, 5-fluorouracil, corticosteroids, retinoids, diclofenac, ingenol mebutate, or imiquimod.
  15. Treatment with liquid nitrogen, surgical excision or curettage within 2 cm of the target isSCC lesion during the 4 weeks prior to the screening visit.
  16. Evidence of current chronic alcohol or drug abuse.
  17. Current enrollment in an investigational drug or device study or participation in such a study within 4 weeks of the screening visit.
  18. In the investigator's opinion, evidence of unwillingness, or inability to follow the restrictions and requirements of the protocol and complete the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04844983


Contacts
Layout table for location contacts
Contact: Nadia Sheibani 301-740-1730 nadiasheibani@sirnaomics.com

Locations
Layout table for location information
United States, Florida
Center for Clinical and Cosmetic Research Recruiting
Aventura, Florida, United States, 33180
Contact: Jaclyn Riley    305-933-6716    j.riley@admcorp.com   
Principal Investigator: Mark Nestor, MD         
Sponsors and Collaborators
Sirnaomics
Layout table for additonal information
Responsible Party: Sirnaomics
ClinicalTrials.gov Identifier: NCT04844983    
Other Study ID Numbers: SRN-705-008
First Posted: April 14, 2021    Key Record Dates
Last Update Posted: May 27, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Squamous Cell
Carcinoma in Situ
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell